Aligos Therapeutics reported progress in their Phase 2 B-SUPREME study of pevifoscorvir sodium, enrolling subjects globally for chronic hepatitis B virus infection treatment. Interim data expected in 2026. Additional data on pevy to be shared at an upcoming conference. The company is also exploring potential partnerships for ALG-055009 in obesity and MASH.
Aligos disclosed financial results for the third quarter of 2025, reporting $99.1 million in cash, compared to $56.9 million in 2024. Net loss was $31.5 million, with increased R&D expenses of $23.9 million and G&A expenses of $5.2 million. Interest income was $1.1 million, with a loss of $4.2 million in fair value of warrants.
Aligos Therapeutics, a Nasdaq-listed biotech company, focuses on developing treatments for liver and viral diseases. Their pipeline includes pevifoscorvir sodium for HBV infection and ALG-055009 for obesity and MASH. The company aims to bring innovative therapies to address unmet medical needs. Aligos Therapeutics, Inc. reported a loss of $31,537 for the third quarter of 2025. Operating expenses totaled $29,102, with revenue from customers at $741. The company’s cash and cash equivalents were $41,946, with total assets at $109,764. Liabilities stood at $37,931, with a total stockholders’ equity of $71,833.
The risks and uncertainties facing Aligos include challenges in drug development, clinical trial design, regulatory approvals, and manufacturing. The company’s ability to protect its intellectual property, access capital resources, and navigate global events are also key concerns. Aligos has filed reports with the SEC detailing these risks and uncertainties.
Investors can contact Aligos Therapeutics’ Vice President of Investor Relations & Corporate Communications, Jordyn Tarazi, at +1 (650) 910-0427 or [email protected] for more information. The company’s financial statements for the third quarter of 2025 show a loss of $31,537 and total assets of $109,764. Operating expenses were $29,102, with revenue from customers at $741.
Read more at GlobeNewswire: Aligos Therapeutics Reports Recent Business Progress and